<DOC>
	<DOCNO>NCT01345318</DOCNO>
	<brief_summary>This multi-center Phase 2 , open label , safety extension study subject moderate severe CD anti-TNF inadequate responder . Subjects eligible study complete 12-week induction period study B0151003 enrol either responder non responder .</brief_summary>
	<brief_title>B0151005 Open-Label Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subjects previously enrol study B0151003 complete blind 84 day ( 12 week ) induction period . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Women childbearing potential , sexual intercourse non surgically sterilize male partner , must agree commit use highly effective method birth control sign ICD 26 week Final Study Evaluation 62 week last dose investigational product subject terminate early study . Subjects complete Day 84 ( Week 12 ) study B0151003 , experience serious event ( ) relate investigational product , unstable medical condition , reason , opinion investigator , would preclude entry inclusion study . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study . Received prohibited treatment study B0151003 , opinion investigator , compromise safety efficacy study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>Crohn 's Disease Activity Index ( CDAI )</keyword>
</DOC>